TY - JOUR
T1 - Current Status and Needs of Long-Term Follow-Up Clinics for Hematopoietic Cell Transplantation Survivors
T2 - Results of a Nationwide Survey in Japan
AU - Kurosawa, Saiko
AU - Mori, Ayako
AU - Tsukagoshi, Mayumi
AU - Onishi, Yasushi
AU - Ohwada, Chikako
AU - Mori, Takehiko
AU - Goto, Hideki
AU - Asano-Mori, Yuki
AU - Nawa, Yuichiro
AU - Hino, Masayuki
AU - Fukuchi, Tomoko
AU - Mori, Yasuo
AU - Yamahana, Reiko
AU - Inamoto, Yoshihiro
AU - Fukuda, Takahiro
N1 - Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy
PY - 2020/5
Y1 - 2020/5
N2 - With increasing focus on the importance of long-term survivorship care after allogeneic hematopoietic cell transplantation (allo-HCT), more institutions have been establishing long-term follow-up (LTFU) clinics. Currently, however, with varying volumes of HCT procedures and resources, there is no standardized operation of these clinics in HCT centers. We conducted a nationwide questionnaire survey to characterize the current operation of LTFU clinics in Japan. We targeted 271 HCT centers (189 adult and 82 pediatric) that registered allo-HCT cases to the national transplant registry database. The response rate was 69%, and 117 of the 188 participating centers (62%) had an established LTFU clinic. The most frequent reason cited for not operating an LTFU clinic was a “lack of human resources,” especially nurses. Most centers with an LTFU clinic targeted allo-HCT recipients, although autologous HCT survivors were followed up at 18% of adult centers and 48% of pediatric centers. Ninety-two percent of centers did not terminate LTFU at a specific time point, and 56% recommended that patients visit the LTFU clinic beyond 5 years after HCT. Fifteen of 20 pediatric centers indicated that they did not routinely refer survivors who underwent HCT at a young age to an adult HCT center for their adulthood LTFU. We found that staffing and standard practices varied widely among centers, and that most centers continued to see long-term HCT survivors at their own outpatient clinics. The development of common LTFU tools may help standardize LTFU practices and facilitate efficient transitions.
AB - With increasing focus on the importance of long-term survivorship care after allogeneic hematopoietic cell transplantation (allo-HCT), more institutions have been establishing long-term follow-up (LTFU) clinics. Currently, however, with varying volumes of HCT procedures and resources, there is no standardized operation of these clinics in HCT centers. We conducted a nationwide questionnaire survey to characterize the current operation of LTFU clinics in Japan. We targeted 271 HCT centers (189 adult and 82 pediatric) that registered allo-HCT cases to the national transplant registry database. The response rate was 69%, and 117 of the 188 participating centers (62%) had an established LTFU clinic. The most frequent reason cited for not operating an LTFU clinic was a “lack of human resources,” especially nurses. Most centers with an LTFU clinic targeted allo-HCT recipients, although autologous HCT survivors were followed up at 18% of adult centers and 48% of pediatric centers. Ninety-two percent of centers did not terminate LTFU at a specific time point, and 56% recommended that patients visit the LTFU clinic beyond 5 years after HCT. Fifteen of 20 pediatric centers indicated that they did not routinely refer survivors who underwent HCT at a young age to an adult HCT center for their adulthood LTFU. We found that staffing and standard practices varied widely among centers, and that most centers continued to see long-term HCT survivors at their own outpatient clinics. The development of common LTFU tools may help standardize LTFU practices and facilitate efficient transitions.
KW - Allogeneic hematopoietic cell transplantation
KW - Late effects
KW - Long-term follow-up
KW - Survivorship
KW - Transition
UR - http://www.scopus.com/inward/record.url?scp=85081314169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081314169&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2020.01.008
DO - 10.1016/j.bbmt.2020.01.008
M3 - Article
C2 - 31962164
AN - SCOPUS:85081314169
SN - 1083-8791
VL - 26
SP - 949
EP - 955
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 5
ER -